The Study Tamoxifen and Raloxifene, or STARS, - проектое clinical test sees as medicine raloxifene is compared with medicine tamoxifen in reduction of incidence breast cancer in postmenopausal woman, who - in raised risk disease. (See total of the protocol.) One of most big breast cancer of the prevention concerns with ever, STAR occurred in more, than 500 centres through the UNITED STATES, Canada, and PUERTO RICO.

The Initial results of the STAR show that medicine raloxifene such efficient as tamoxifen in reduction breast cancer risk of the womans in test. In STAR, both medicines reduced the risk to develop invasive breast cancer beside 50 percents. Besides, within analysis, women(woman), who were nominated to take raloxifene daily and, which was  for average around four years, had 36 percents smaller uterine cancer and 29 percents smaller blood clot than women(woman), who were nominated to take tamoxifen. The Uterine paradise, particularly endometrial paradise, - rare but serious side effect tamoxifen. As tamoxifen so and raloxifene known that to enlarge the feminine risk blood clot.

The Researchers with National Surgical Useful Breast and Project of the Gut (NSABP), профинансированная Cooperative Group NCI, проведшая test. THE STAR was financed originally NCI.

The Relationship on the left this pages will send You that more detailed information on test and result while, including row press material (see STARRY Background).

The Breast cancer is a critical medical problem: more, than 212,000 womans will are diagnosed doggy style bosom in United Staff this year and more, than 30,000 умрет disease.

Tags: Evista, Raloxifene, tamoxifene

This entry was posted on Пятница, Декабрь 25th, 2009 at 15:00 and is filed under Pharmacy news, Woman Health, Новости. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.